Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Not applicable Interventional Results available

Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women

NCT00127231
View directory record Official record
Conditions
HIV Infections, Alcoholism
Interventions
Brief alcohol intervention based on Project Treat, Standard care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Case Management Alternatives for African American Women at High Risk for HIV

NCT00780260
View directory record Official record
Conditions
HIV
Interventions
strengths-based case management
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 21, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People

NCT00919724
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 21, 2026, 2:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Community-University Approach to Preventing HIV

NCT03938077
View directory record Official record
Conditions
HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage, Alcohol Use, Mental Health, Tobacco Use, HIV Testing
Interventions
Storytelling 4 Empowerment
Device
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

NCT02330419
View directory record Official record
Conditions
Binge Drinking, HIV
Interventions
Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment
Drug · Behavioral · Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Glutathione and Function in HIV Patients

NCT02348775
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
GlyNAC (combination of glycine and n-acetylcysteine)
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Mobile Health Application to Improve HIV Medication Adherence

NCT02676128
View directory record Official record
Conditions
HIV, Medication Adherence, Mobile Health
Interventions
Twine Collaborative Care Application, Information-Motivation-Behavioral Skills Model of ART Adherence
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women

NCT00125983
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

NCT04554966
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 21, 2026, 2:05 PM EDT
Completed No phase listed Observational

Effect on HIV Medications on EPC Cells

NCT03782142
View directory record Official record
Conditions
AIDS
Interventions
Tenofovir, Rilpivirine, Prezcobix, Dolutegravir
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 21, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Ending the HIV Epidemic: An All-facility Intervention for Patient and Healthcare Staff Well-being

NCT05785169
View directory record Official record
Conditions
Stigma, HIV, Well-Being, Psychological
Interventions
All-facility Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 4 Interventional

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

NCT00000894
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 21, 2026, 2:05 PM EDT
Completed No phase listed Observational

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

NCT00244803
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Effects of Creatine and Resistance Exercise Training in People With HIV Infection

NCT00484627
View directory record Official record
Conditions
HIV Infections
Interventions
Use of creatine monohydrate (a dietary supplement), Progressive resistance exercise training
Procedure · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
COBI, DRV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Results available

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

NCT03618056
View directory record Official record
Conditions
HIV Infections, Systemic Lupus Erythematosus
Interventions
AIDSVAX® B/E
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/zidovudine, Efavirenz, Raltegravir
Drug
Lead sponsor
Westat
Other
Eligibility
16 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Persuasive Health Communication Intervention for HIV/HCV

NCT05968573
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
Interventions
Video Format with Captions, Video Format without Captions, Health Educator
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Not applicable Interventional

A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

NCT00002054
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 2:05 PM EDT